Cite
HARVARD Citation
Harbeck, N. et al. (n.d.). 1815 A double blind phase 3 trial of fulvestrant with placebo or palbociclib in pre- and post-menopausal women with hormone receptor-positive (HR+ve), HER2-negative (HER2-ve) metastatic breast cancer (MBC) that progressed on prior endocrine therapy (PALOMA 3): Detailed analysis of patient-reported outcomes. European journal of cancer. pp. S270-S271. [Online].